Phibro Animal Health Corporation
NASDAQ:PAHCDrug Manufacturers - Specialty & Generic
+$0.38 today
- Market cap
- $1.44B
- Beta
- 0.46
- P/E (TTM)
- 13.3
- EPS (TTM)
- $2.35
- Dividend yield
- 1.54%
Volume 0.11M
Average 0.37M
PAHC Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Phibro Animal Health CorporationNASDAQ: PAHC
Accounts Receivables · Q3 FY2026 · quarter ended Mar 2026
Accounts receivables growth accelerates
Q3 FY2026 accounts receivables of $4.78M (cash outflow) rose 37.6% year over year, ahead of the -58.4% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at +32.7% a year.
Context
- Accounts receivables amounted to 4.3% of revenue in FY2025, up 3.4 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +37.6% holds above the trailing-twelve-month pace of -58.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (55.21M) USD
- Year-over-year change
- -536.2%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | (55.21M) | -536.2% |
| FY2024 | 2024-06-30 | (8.68M) | -262.7% |
| FY2023 | 2023-06-30 | 5.34M | +122.6% |
| FY2022 | 2022-06-30 | (23.63M) | -29.7% |
| FY2021 | 2021-06-30 | (18.21M) | — |
Accounts Receivables vs competitors
How PAHC compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -58.4% is the 3rd highest of 5, against a peer median of -25.2%.
- Accounts receivables amounts to 1.1% of revenue for PAHC, versus a peer median of 1.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.09B USD | — | +19.2% | 1.6% | |
| LTM Jun 2026 | $214M USD | +49.7% | +19.9% | 2.2% | |
| FY2025 | CN¥61.41M CNY | +443.0% | — | 52.8% | |
| LTM Mar 2026 | $17.03M USD | -58.4% | +32.7% | 1.1% | |
| LTM Aug 2026 | $407K USD | -101.7% | — | 0.0% | |
| LTM Sep 2026 | $0 USD | -100.0% | — | 0.0% | |
| Peer median (excluding PAHC) | — | -25.2% | +19.5% | 1.6% | |
Competitors are the stored peer set for PAHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Net Income | 54.39M | 49.18M | 32.61M | 2.42M | 48.26M |
| Depreciation & Amortization | 31.89M | 32.71M | 34.01M | 36.18M | 45.61M |
| Deferred Income Tax | (2.18M) | (806K) | (2.84M) | (7.84M) | (4.88M) |
| Stock-Based Compensation | 1.13M | 0 | 0 | 475K | 717K |
| Change in Working Capital | (29.87M) | (44.64M) | (41.13M) | 33.11M | (21.56M) |
| Accounts Receivables | (18.21M) | (23.63M) | 5.34M | (8.68M) | (55.21M) |
| Inventory | (12.5M) | (47M) | (11.22M) | 2.64M | (44.29M) |
| Accounts Payables | 3.18M | 26.36M | (22.83M) | 12M | 45.56M |
| Other Working Capital | (2.34M) | (373K) | (12.42M) | 27.15M | 32.39M |
| Other Non-Cash Items | (7.04M) | (4.79M) | (9.34M) | 23.25M | 11.98M |
| Operating Cash Flow | 48.31M | 31.65M | 13.31M | 87.59M | 80.12M |
| Capital Expenditures | (29.32M) | (37.04M) | (51.79M) | (41.24M) | (38.29M) |
| Acquisitions (Net) | 29.32M | (13.51M) | 0 | (3.28M) | (286.53M) |
| Purchases of Investments | (74M) | (64.1M) | (40M) | (65.52M) | (14M) |
| Sales of Investments | 86M | 91.45M | 17M | 61.52M | 49M |
| Other Investing Activities | (30.58M) | 620K | 776K | 326K | 1.13M |
| Investing Cash Flow | (18.58M) | (22.58M) | (74.02M) | (48.19M) | (288.69M) |
| Debt Repayment | 5.38M | 40.63M | 42.69M | 12.71M | 235.99M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (19.43M) | (19.44M) | (19.44M) | (19.44M) | (19.45M) |
| Other Financing Activities | (2.94M) | (4.84M) | 3.74M | (31K) | (9.4M) |
| Financing Cash Flow | (17M) | 16.34M | 26.99M | (6.77M) | 207.13M |
| Effect of Forex Changes | 1.14M | (1.37M) | 754K | (3.3M) | (1.14M) |
| Net Change in Cash | 13.87M | 24.04M | (32.97M) | 29.33M | (2.57M) |
| Free Cash Flow | 18.99M | (5.4M) | (38.48M) | 46.36M | 41.83M |
Phibro Animal Health Corporation
NASDAQ:PAHC
Intrinsic Alpha fair value
Locked
Current Price
$35.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.